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a Radiotherapy Ward I, Greater Poland Cancer Centre, Poznan, Poland
b Department of Medical Physics, Greater Poland Cancer Centre, Poznan, Poland
c Department of Radiotherapy, Greater Poland Cancer Centre, Poznan, Poland
a  r  t  i  c  l  e  i  n  f  o
Article history:
Received 26 February 2016
Received in revised form
18  January 2017
Accepted 25 February 2017
Available online 4 April 2017
Keywords:
Stereotactic body radiation therapy
(SBRT)
Liver metastases
a  b  s  t  r  a  c  t
Aim: The main purpose of this work is to give a technical description and present the prop-
erties  of the liver SBRT protocol implemented in the Greater Poland Cancer Centre (GPCC)
in  Poznan, Poland.
Background: Stereotactic body radiation therapy (SBRT) for liver metastasis is a non-invasive
therapeutic option which enables irradiation of a small target in the body with a high dose.
Materials and methods: This study presents details of our linac-based liver SBRT protocol. Spe-
cial emphasis has been placed on fiducial implantation, patient preparation (CT scanning,
immobilization), treatment planning, and its implementation.
Results: The liver SBRT treatment course implemented in the GPCC consists of three fractions
to  deliver a total of 45 Gy. Fraction delivery details with description of patient positioning
(localization of liver metastasis) are presented below.Fiducial markers Conclusions: The literature validation of the assumptions concerning the steps of the GPCC
linac-based liver SBRT procedure show their potential for an effective and patient friendly
implementation.
©  2017 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.1.  Background
Most of the cancers: colorectal, breast, kidney, lung, pancreas
cancers, often present solitary metastasis or oligometas-
tases in the liver. A surgical resection provides a long
term survival in approximately 30% of patients with the
colorectal carcinoma liver metastases, but only a limited
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1507-1367/© 2017 Greater Poland Cancer Centre. Published by Elsevier (10–25%) percentage of patients is amenable to surgery. Non-
surgical ablation methods include cryotherapy, laser-induced
interstitial thermotherapy, and radiofrequency ablation
which is the most frequently used method. Stereotactic
body radiation therapy (SBRT) is a non-invasive therapeu-
tic option, which enables irradiation of a small target in
the body with a high dose.1–4 The use of SBRT is rapidly
increasing.5–8 Centre, 15th Garbary Street, 61-866 Poznan, Poland.
Sp. z o.o. All rights reserved.


















































Table 1 – Dose constraints to organs at risk.
Organ at risk Dose constraint
Liver (healthy) (liver-PTV) D700  ml < 15 Gy
Kidneys (both) D35% < 15 Gy for kidneys volume
(sum of both kidneys)
D50% < 15 Gy for the kidney
receiving the highest dose
Spinal cord Dmax < 18 Gy
Stomach D1CC < 21 Gy
Esophagus D1CC < 21 Gy
Bowel D1CC < 21 Gy
Heart D1CC < 30 Gy
Duodenum D1CC < 21 Gy
D700  ml – dose received by 700 ml of the analyzed organ.reports of practical oncology and 
.  Aim
he aim of the study is to present the SBRT treatment for liver
etastases using a conventional linear accelerator.
.  Materials  and  methods
t the Greater Poland Cancer Centre (GPCC), for the SBRT
urposes, we  classify patients into those with metastases
n one organ (liver metastases); those with a histopatholog-
cally proven colorectal adenocarcinoma; those after a radical
esection of the primary tumor; inoperable; or those with a
ecurrence after an operation on the liver. The maximum
ccepted diameter of the largest metastasis is 6 cm.  If two
esions of metastases are close to each other, the maximum
iameter is greater (up to 8–9 cm with the lesions contoured
s one connected target). One to four metastases are accepted
hile a tumor is visible on CT scans.
The patient should have status 2 WHO/ECOG; chemother-
py is allowed before and after the study treatment, but the
ast chemotherapy must be within one month before the SBRT.
Exclusion criteria: an uncontrolled extrahepatic disease
nd an uncontrolled primary cancer, a liver cirrhosis.
Before the treatment begins, all patients are discussed
t a meeting of a multidisciplinary team consisting of sur-
eons, medical oncologists, radiation therapists, radiologists
nd hepatologists. At the GPCC, preparation for the stereo-
actic treatment starts by conducting an operation. For the
reatment, internal fiducial markers are implanted near the
iver tumor to allow monitoring the tumor movement  dur-
ng the treatment. While the fiducial markers are typically
mplanted under CT-guidance or ultrasound guidance, at the
PCC the fiducial markers are implanted during the operation.
he tumor at the time of treatment may turn out to be larger
han estimated through CT or ultrasound examinations. The
urgeon or radiation oncologist visually implants 2–4 fiducial
arkers in healthy tissues, in a strategic, non-planer geomet-
ic relationship among one another. The operator can observe
he tumor, measure it if necessary, and can easily observe
he distance between the tumor and the healthy tissue. The
mplantation process becomes easier than the one conducted
hrough the CT guidance. A CT scan treatment planning with
ontrast and slice thickness of 3 mm is conducted about ten
o fourteen days after the fiducial placement. An appropriate
reparation for the SBRT treatment is started by forming the
acuum pillow on which the patient is positioned frameless
n a standard supine position, the patient’s arms are abducted
longside the head, and knee support is utilized.9,10 The CT
mages are acquired at 3 mm slice spacing in different breath-
ng conditions:
 free shallow breathing for planning purpose10,11;
 deep breathing while maintaining position;
 free shallow breathing with contrast enhancement.10All CT scans are transferred to the Eclipse V.10.0 Treat-
ent Planning System (Varian Medical Systems, Palo Alto,
alifornia, USA). A gross tumor volume (GTV) and organsDX% – dose delivered to x% of the analyzed organ.
D1CC – dose delivered to 1cc of the analyzed organ.
at risk (OARs) are delineated by a physician on the free
breathing CT scan.10,30 The gross tumor volume is consid-
ered to be identical with the clinical target volume (CTV) and
expanded by 5 mm margin (the exception being by 10 mm in
the cranio-caudal direction) to create the planning target vol-
ume  (PTV)11–13 for the respiratory motion observed at the time
of simulation. The OARs may include healthy organs (liver
for which the PTV volume is subtracted, kidneys, spinal cord,
stomach, esophagus, bowel, heart). The dose delivered to the
organs is presented in Table 1. Dose constraints to OARs are
adopted to the clinical protocol as proposed by the Interna-
tional Liver Tumor Group.31,32
According to numerous literature findings, the dose is nor-
malized to prescribe 100% of the dose to the mean GTV. At the
same time, jaws and a multileaf collimator (MLC) should be
adopted and fitted to encompass the GTV and PTV volumes
by at least 95% and 67% isodose, respectively.13,26,33
In our treatment protocol (the liver SBRT), we  use 15 Gy in
3 fractions (the total dose 45 Gy).9 The protocol assumes that
the treatment plan is prepared by a three dimensional conven-
tional conformal radiotherapy technique with 6 MV photons
and the dose rate of 600 MU/min. A dosimetric calculation
is conducted using the Anisotropic Analytical Algorithm with
heterogeneity correction.14–16
The geometry of the plan should be proposed taking into
account the tumor size, medical location, boundary, and vas-
culature projection in the treated area.17,30 To enhance dose
homogeneity, field weighting and wedges can be used.
At the GPCC, we use the Varian environment: the Eclipse
v. 10.0 Treatment Planning System. The patients are treated
in a Clinac 2300CD linear accelerator with the On-board
Imager, OBI and 120 Millennium MLC  with 0.5 cm width in the
isocenter.9
4.  Results
In our SBRT protocol three fractions are delivered according to
two proposed schemes: irradiation every second day with the
treatment starting on Monday; or the treatment starting on
Tuesday and ending on Monday. Both schemes are applied in
different cancer centers with three dose fractions delivered in
one week (Erasmus). The total course of the SBRT is completed
d rad160  reports of practical oncology an
within 14 days12,31 and each isocenter is treated within 8
days with each fraction having been delivered.12 Before each
session, a system of wall mounted alignment lasers is used
for initial, daily positioning of the patient. For each fraction,
the set-up is performed using co-registration between the kV
cone beam CT scans (CBCT) and the planning CT scans18–20 to
determine the actual position of the target (fiducial markers
based verification). After making a CBCT based shift, the kV
imaging is taken to confirm the position of the tumor (local-
ization of the fiducial markers position). In our protocol, the
patient set-up is repeated after the first half of the treatment
to correct a possible intra-fraction movement  and after the
daily fraction to observe the final tumor position.9
During and after the treatment, the side effects are gen-
erally mild. Observed toxicities range from grade 1 to 2 in the
CTCAE v.4 (Common Terminology Criteria for Adverse Events).
The most common acute toxicities include nausea, vomiting,
gastritis, and an abdominal or chest wall pain.21,25,27
Now, we  start the liver SBRT with 4D CT planning and the
treatment on the CyberKnife.
5.  Discussion
In the last few years, the SBRT has been used as a non-invasive,
loco-regional treatment for many  primary and secondary
tumors with promising results25 Some retrospective16,17 and
some prospective14,22–24 studies have investigated the effi-
cacy of the SBRT in the treatment of liver metastases from
various primary tumors. In general, patients with up to four
metastases, and with the maximum diameter of the largest
metastasis of no more  than 40 mm,  are selected for the SBRT
treatment.28 However, some authors describe treatment pro-
cedures performed for 110-mm hepatic metastasis3,15 that are
also applicable to patients with metastases in two organs. The
SBRT requires a highly precise dose planning and delivery. In
the simulation phase, the patient is immobilized with a per-
sonalized vacuum pillow. An abdominal compression device
should be used to reduce the organ motion related to the
respiratory excursion.34 A contrast-free computed tomogra-
phy (CT) scan and a three-phase contrast-enhanced CT scan
are acquired. The potential of dealing with tumor motion in
the SBRT is improved by the introduction of a 4-dimensional
CT (4D CT) imaging. This imaging tool is widely used to accu-
rately compensate for exhalation and inhalation.11 The 4D CT
scan enables contouring for the internal target volume while
incorporating the tumor motion, as it is visualized through-
out the breathing cycle. Without the CT, which enables to
achieve 4D scanning or eventually ultra-slow scanning, we
prepare the reconstruction in different modes, which, after
registration, gives us the information about the tumor expan-
sion in different breathing conditions.9 In the CyberKnife,
before each treatment, the Xsight spine positioning is per-
formed to check the body alignment and to verify possible
fiducials migration.11 Without the CyberKnife, the guidance
on the basis of images obtained using the CT scanners in
the treatment room (the helical MV  CT or the kV cone-
beam CT scanners) enables to guide and monitor the fraction
treatment. Similar to the CyberKnife Synchrony, fiducials are
recommended for CBCT positioning. Unfortunately, due to aiotherapy 2 2 ( 2 0 1 7 ) 158–162
poor image  contrast between the tumor and the liver tissues,
without fiducials, a tumor-based match between planning and
the pre-treatment CTs is unfeasible9,11 Worm et al.11 in their
study report that using the CT-guidance helps prevent critical
errors connected with initial tumor positioning and ensure a
proper radiation delivery exactly to the target. In clinics with-
out a fiducial implantation, the bony landmarks fusion for the
liver SBRT pre-treatment verification is the most commonly
used procedure. Unfortunately, due to the independent move-
ment between the liver and bones11, such a set-up procedure
introduces another source of uncertainty during irradiation,
which must be taken into account while applying the CTV-to-
PTV margin.
The prescription doses generally range from 30 to 60 Gy in
3 fractions, although a publication describes a phase II trial
where a higher prescription dose of 75 Gy in 3 fractions was
delivered.23 According to the SBRT assumptions, the highest
dose per fraction (from 5.0 Gy up to 25.0 Gy)10,12,28 is delivered
to small target volumes. Even if the highest scheme of dose per
fraction is used, all literature reports underline that if a dose
reduction is needed, based on acceptable location of a tumor
close to the OARs (esophagus, stomach, bowel and kidneys), a
lower dose level for the target is to be chosen. When there is
more  than one metastasis, it is acceptable to choose a lower
dose level for the target which is located near the critical struc-
ture and a higher dose level for the non-critical targets.13,15
Schefer et al.12 enrolled 16 patients with liver metastases in a
phase I trial. They reported that it was possible to increase
the radiation dose to 60 Gy in three fractions without any
toxicity,22,29 and the local control rate was 93% in the first year
after the SBRT. Hoyer et al.13 published results of a Danish
phase II study of the liver metastases treated with the total
dose of 45 Gy in three fractions. The local control rates after
1 and 2 years after the SBRT were 89% and 79%, respectively.
Kavanagh at al.21 reported an actuarial local control rate of
93% after 18 months.
Most studies showed a low toxicity profile with a ≥G3 tox-
icity rate of 1–10% and the incidence of the radiation-induced
liver disease (RILD) of less than 1%. In phase II trial by Scorsetti
et al.23 on 61 patients, no RILD was observed using a dose con-
straint allowing no more  than 700 mL  of the uninvolved liver
to receive 15 Gy or greater in 3 fractions. The most common G2
toxicities included a transient hepatic transaminase increase
approximately 3 months after the SBRT13,14; and gastrointesti-
nal, soft-tissue complications related to lesions close to the
duodenum, bowel, skin and ribs.
Good selection criteria for patients with liver metastases
who are candidates for SBRT remain a controversial topic.
A multidisciplinary tumor board discussion is recommended
before each qualification. For discussion purposes, candidates
for SBRT can be divided into three categories: suitable, cau-
tionary and unsuitable patients.23,34 Selection criteria may be
based on: the lesion number, the lesion diameter, the distance
from the OARs, the liver function and patients’ conditions.6.  Conclusions
The goal of the SBRT is to deliver a high dose to the target,
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he dose to the surrounding healthy tissue, thereby poten-
ially decreasing the chances of complication. For the patients,
mplanting fiducial markers during the operation is a safer,
elatively painless method. As our treatment approach is
ased on the SBRT delivery with no motion restrictive external
mmobilization, breathing instructions and frequent online
maging cannot be neglected. Due to the mentioned capabil-
ty of delivering various doses with different equipment, the
iterature validation of our liver SBRT protocol finds it suitable
or patients with liver metastases, and highlights its potential
or an effective and patient friendly delivery.
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